Efficacy and safety of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma in Japan: Results of the Japan Clinical Oncology Group single-arm confirmatory trial (JCOG1605)

The primary endpoint progression-free survival did not meet the predefined threshold. However, the response rate and overall survival were better than expected, and there were no safety issues. Therefore, pazopanib may be a treatment option for patients with paclitaxel-pretreated primary cutaneous angiosarcoma. (231/350 words).

Authors

Institutions

Publication Details

Journal
British Journal of Dermatology
Published
2026-03-02
DOI
https://doi.org/10.1093/bjd/ljag071
Primary Topic
Vascular Tumors and Angiosarcomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma in Japan: Results of the Japan Clinical Oncology Group single-arm confirmatory trial (JCOG1605)

Yukiko Kiniwa, E. Nakano, Azusa Hiura, K. Namikawa et al.
British Journal of Dermatology
Vascular Tumors and Angiosarcomas
article

Efficacy and safety of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma in Japan: Results of the Japan Clinical Oncology Group single-arm confirmatory trial (JCOG1605)

Yukiko Kiniwa, E. Nakano, Azusa Hiura, K. Namikawa, Tomoe Nakagawa, Ikko Muto, Jiro. Uehara, Masayuki Yokoyama, Ayano Maruyama, Hiroshi Yamano- Uchi, A. Takahashi, Y. Nakamura, T. Takenouchi, Naoya Yamazaki, Taku Maeda, Takuya Maeda, Naohito Hatta, Kohei Oashi, Yusuke Sano, Yoshitsugu Shibayama, Takeru Funakoshi, Shoichiro Mori, Haruhiko Fukuda, Dai Ogata
article en

Abstract

The primary endpoint progression-free survival did not meet the predefined threshold. However, the response rate and overall survival were better than expected, and there were no safety issues. Therefore, pazopanib may be a treatment option for patients with paclitaxel-pretreated primary cutaneous angiosarcoma. (231/350 words).

British Journal of Dermatology
Kurume University (JP), Shinshu University (JP), Asahikawa Medical University (JP), Kyoto Prefectural University (JP), Keio University (JP), Hokkaido University (JP), Tokyo Metropolitan Komagome Hospital (JP), Fukuoka University (JP), Kyoto Prefectural University of Medicine (JP), National Cancer Centre Japan (JP), Toyama Prefectural Central Hospital (JP), National Cancer Center (US), Niigata Cancer Center Hospital (JP), National Hospital Organization Kyushu Cancer Center (JP), Kurume University Hospital (JP), Keio University Hospital (JP), University of Tokyo Hospital (JP), Saitama Cancer Center (JP), Saitama International Medical Center (JP), National Cancer Center Hospital East (JP), Saiseikai Fukuoka General Hospital (JP), Japanese Foundation For Cancer Research (JP), Nagoya University (JP), The University of Tokyo (JP), Saitama Medical University (JP), Teikyo University (JP)
Good health and well-being
Openalex Percentile: Top 34%
Vascular Tumors and Angiosarcomas
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.